Why the 2019 @BLS_gov Jobs report is a red flag for American #healthcare: bls.gov/news.release/e…
A thread to explain 1. You may recall that in late December 2017, #healthcare jobs overtook retail to become #1 for the first time in US history
@BLS_gov 2. Since that time, the US has added ~1 million more #healthcare jobs, >50,000 more in 2019 than 2018. No sector grew more in 2019.
(NB Education + healthcare sum is ~90% healthcare related)
@BLS_gov@EricMorath@TheAmaraReport 4. Human capital, i.e. the workforce, is the #1 driver of costs of healthcare. In the US we now pay > $11,000 per person with the worst major outcomes of all 36 @OECD countries. There are no data to suggest that more labor support will improve outcomes. growthevidence.com/growth-comment…
@BLS_gov@EricMorath@TheAmaraReport@OECD 5. So this is a feed the (broken) beast model. Nothing is being done to address it; the job growth is just celebrated.
Whereas the UK (which has better outcomes at half the cost) undertook an in-depth review & is implementing many worthy strategies topol.hee.nhs.uk
We've known about KP.3's marked growth advantage since April and could have made the call then to make the new booster. That would have been aligned well with the current wave (available in July) 2/5 erictopol.substack.com/p/are-we-flirt…
But the FDA has tried to force fit Covid into an annual shot like flu, even though all data tells us it doesn't follow an annual pattern. Even the CDC acknowledges this now
3/5cdc.gov/ncird/whats-ne…
New CDC genomic data shows continued rise of the KP.3 variant that accounts for 1 of 3 Covid cases.
LB.1 is gaining, too, as JN.1 fades away
This variant growth advantage plot by @BenjMurrell (H/T @siamosolocani) shows why this is the case. Note KP.3 is the one at far left w/ almost 3-fold advantage to JN.1.
Reinforces why the decision to develop the KP.2 vaccine booster (instead of JN.1) was a good one
Spike mutation map to show the differences betweem KP.3 and JN.1 (and LB.1, KP.2)
The connection between #SARSCoV2 and neurodegeneration
@TheLancetNeuro
Quotes below: 1. SARS-CoV-2 infection should be considered as a risk factor for Alzheimer’s disease, even though the distinction between causation versus disease acceleration is not clear.thelancet.com/journals/laneu…
2. Inflammation in patients with COVID-19, and controlled experiments show prolonged neuro-inflammation after mild SARS-CoV-2 infection
in macaques.
3. A direct correlation has been reported
between prior SARS-CoV-2 infection and increased risk
of Alzheimer’s disease (figure).
4. So far, the estimated lifetime cumulative risk of dementia due to hospitalisation for any viral infection is 1·48 (95% CI 1·15–1·91).
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good.
My oped on the JN.1 variant and the 2nd biggest US wave of infections (after Omicron) since the pandemic began
@latimes @latimesopinion #LongCovid latimes.com/opinion/story/…
Recent @CDCgov #SARSCoV2 wastewater data for current wave (vs Omicron Jan 2022 and subsequent waves), graph by @luckytran
Sorry, @washingtonpost, but this is not "another Covid-19 uptick" as you put it in your Health Alert. You ignore the best metric for infections that we have at present—wastewater—focusing only on hospitalizations washingtonpost.com/health/2024/01…